EZH2 and cervical carcinoma: Considering that EZH2 inhibitors can potentially reverse aberrant DNA patterns, methylation-specific modifications in both HPV- and HPV+ cervical cancer should be analysed to further determine effectiveness of EZH2 inhibitors [83,84,85,86,87].